COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy

ABSTRACT Objectives: There are no comparative studies between patients belonging to the first and second waves of the SARS-CoV-2 pandemic, the virus triggering coronavirus disease 2019 (COVID-19). In this retrospective observational study, we analyzed the clinical characteristics and the short-term outcomes of two groups of laboratory-confirmed COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS) belonging to two different waves of the pandemic. Methods: We analyzed 97 consecutive patients from 11 March 2020 to 31 May 2020 and 52 consecutive patients from 28 August 2020 to 15 October 2020. Results: Patients belonging to the second wave were younger, had a lower number of concomitant chronic conditions (multimorbidity), and had a milder clinical phenotype. Medical treatments and respiratory support use have changed during the COVID-19 pandemic, based on different laboratory results and disease clinical features. Patients in the second wave had better short-term clinical outcomes, with lower death rates and more step-down transfers to a general ward. Conclusion: The present findings show a clear phenotypic difference in patients hospitalized at different stages of the COVID-19 pandemic in Italy. These results can help to stratify clinical risk and to better tailor medical treatments and respiratory support for patients with ARDS and COVID-19 pneumonia.

[1]  V. Procacci,et al.  More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy , 2021, Respiratory Research.

[2]  F. Panza,et al.  Bilevel and continuous positive airway pressure and factors linked to all-cause mortality in COVID-19 patients in an intermediate respiratory intensive care unit in Italy , 2020, Expert review of respiratory medicine.

[3]  Marcos Pereira,et al.  Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis , 2020, Critical reviews in food science and nutrition.

[4]  D. Raoult,et al.  Asymptomatic hypoxia in COVID-19 is associated with poor outcome , 2020, International Journal of Infectious Diseases.

[5]  J. Ramos-Rincón,et al.  Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19 , 2020, Journal of clinical medicine.

[6]  A. Rodríguez-Molinero,et al.  Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients , 2020, PloS one.

[7]  C. D. Dela Cruz,et al.  Does inflammation help during COVID-19? , 2020, ERJ Open Research.

[8]  R. Gómez-Huelgas,et al.  Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19 , 2020, Journal of clinical medicine.

[9]  F. Della Corte,et al.  Change over time of COVID-19 hospital presentation in Northern Italy , 2020, European Journal of Internal Medicine.

[10]  A. Borobia,et al.  Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications , 2020, European journal of heart failure.

[11]  Dina N. Greene,et al.  Decreasing median age of COVID-19 cases in the United States—Changing epidemiology or changing surveillance? , 2020, medRxiv.

[12]  O. Resta,et al.  Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19 , 2020, Journal of Endocrinological Investigation.

[13]  Wei Liu,et al.  COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study , 2020, Hypertension Research.

[14]  A. Verma,et al.  Nasal ACE2 Levels and COVID-19 in Children. , 2020, JAMA.

[15]  J. Wolchok,et al.  The many faces of the anti-COVID immune response , 2020, The Journal of experimental medicine.

[16]  M. Zuin,et al.  Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission , 2020, British Journal of Anaesthesia.

[17]  H. Hou,et al.  The laboratory tests and host immunity of COVID-19 patients with different severity of illness. , 2020, JCI insight.

[18]  L. Camporota,et al.  COVID-19 pneumonia: different respiratory treatments for different phenotypes? , 2020, Intensive Care Medicine.

[19]  Z. Tong,et al.  Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China , 2020, JAMA network open.

[20]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[21]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[22]  A. Verma,et al.  COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? , 2020, JAMA.

[23]  O. Resta,et al.  Baseline characteristics and outcomes of COVID-19 patients admitted to a Respiratory Intensive Care Unit (RICU) in Southern Italy , 2020, Multidisciplinary respiratory medicine.

[24]  S. Keenan,et al.  Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure , 2017, European Respiratory Journal.

[25]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[26]  M. Holick,et al.  Factors that influence the cutaneous synthesis and dietary sources of vitamin D. , 2007, Archives of biochemistry and biophysics.

[27]  R. Bone,et al.  Noninvasive respiratory care unit. A cost effective solution for the future. , 1988, Chest.

[28]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .